

## DAFTAR PUSTAKA

1. Rengganis I, Baratawidjaja KG. *Imunologi dasar*. 12th ed. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2018.
2. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. *Curr Opin Immunol*. 2023 Feb 1;80.
3. Samuels H, Malov M, Saha Detroja T, ben Zaken K, Bloch N, Gal-Tanamy M, *et al*. Autoimmune Disease Classification Based on PubMed Text Mining. *J Clin Med*. 2022 Aug 1;11(15).
4. Khairani AF, Karina M, Siswanti LH, Dewi MM. Clinical profile of pediatric Guillain-Barré syndrome: A study from national referral hospital in West Java, Indonesia. *Biomedical and Pharmacology Journal*. 2019;12(4):2043–8.
5. Shang P, Zhu M, Wang Y, Zheng X, Wu X, Zhu J, *et al*. Axonal variants of Guillain-Barré syndrome: an update. *J Neurol*. 2021 Jul 5;268(7):2402–19.
6. Cavalcante J, Cembraneli PN, Cavalcante R, Fernandes V, Junior V, Cavalcante JE. Atypical manifestations in children with Guillain-Barré syndrome. *Edorium Journal of Neurology* [Internet]. 2020;7:100014–20. Available from: [www.edoriumjournalofneurology.com](http://www.edoriumjournalofneurology.com)
7. Yosha-Orpaz N, Aharoni S, Rabie M, Nevo Y. Atypical Clinical Presentations of Pediatric Acute Immune-Mediated Polyneuropathy. *J Child Neurol*. 2019 Apr 1;34(5):268–76.
8. Zheng P, Tian DC, Xiu Y, Wang Y, Shi FD. Incidence of Guillain-Barre syndrome (GBS) in China: A national population-based study. *Lancet Reg Health West Pac* [Internet]. 2022;18:100302. Available from: <https://doi.org/10.1016/j.lanreg.2022.100302>
9. Bragazzi NL, Kolahi AA, Nejadghaderi SA, Lochner P, Brigo F, Naldi A, *et al*. Global, regional, and national burden of Guillain-Barré syndrome and its underlying causes from 1990 to 2019. *J Neuroinflammation*. 2021 Dec 1;18(1).
10. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Vol. 397, *The Lancet*. Elsevier B.V.; 2021. p. 1214–28.
11. Morales-Ruiz V, Juárez-Vaquera VH, Rosetti-Sciutto M, Sánchez-Muñoz F, Adalid-Peralta L. Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis. *Autoimmun Rev*. 2022 Mar;21(3):103019.
12. Iqbal R, Asad MJ, Shah MB, Mahmood RT, Siddiqi S. Clinical and biochemical profile of guillain barré syndrome in Pakistan. *Neurosciences*. 2021;26(3):242–7.
13. Chiu ATG, Chan RWK, Yau MLY, Yuen ACL, Lam AKF, Lau SWY, *et al*. Guillain-Barré syndrome in children – High occurrence of Miller Fisher syndrome in East Asian region. *Brain Dev*. 2022 Nov 1;44(10):715–24.

14. Bullo N, Shaikh JA, Afzal M, Kumar S, Fatima M, Kumar D. Electromyographic Findings in Guillain-Barré Syndrome Patients. *J Pharm Res Int*. 2022 Apr 29;6–13.
15. Berciano J. Axonal pathology in early stages of Guillain-Barré syndrome. *Neurología (English Edition)*. 2022 Jul;37(6):466–79.
16. Aragonès JM, Altimiras J, Alonso F, Celedón G, Alfonso S, Roura P, *et al*. Incidence and clinical characteristics of Guillain-Barré syndrome in Osona (Barcelona, Spain), 2003-2016 [Internet]. Vol. 36, *Neurología*. 2021. Available from: [www.elsevier.es/neurologia](http://www.elsevier.es/neurologia)
17. Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, *et al*. Regional variation of Guillain-Barré syndrome. *Brain*. 2018 Oct 1;141(10):2866–77.
18. Rahman RS, Bauthman MS, Alanazi AM, Alsillah NN, Alanazi ZM, Almuhaysin MI, *et al*. Guillain–Barré syndrome: pathophysiology, etiology, causes, and treatment. *Int J Community Med Public Health*. 2021 Jun 25;8(7):3624.
19. Kılıç B, Güngör S, Özgör B. Clinical, electrophysiological findings and evaluation of prognosis of patients with Guillain-barré syndrome. *Turkish Journal of Pediatrics*. 2019;61(2):200–8.
20. Doets AY, Jacobs BC, van Doorn PA. Advances in management of Guillain–Barré syndrome. Vol. 31, *Current Opinion in Neurology*. Lippincott Williams and Wilkins; 2018. p. 541–50.
21. Sidow NO, Hassan MS. Intravenous immunoglobulin treatment with prognosis for the first six months of Guillain–Barré Syndrome in Somalia: Case series. *Annals of Medicine and Surgery*. 2022 Dec;84:104816.
22. Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, *et al*. Diagnosis and management of Guillain–Barré syndrome in ten steps. *Nat Rev Neurol*. 2019 Nov 1;15(11):671–83.
23. Lupu VV, Miron I, Cianga AL, Gavrilovici C, Grigore I, David AG, *et al*. Diagnostic Pitfalls in Guillain–Barré Syndrome: Case Report and Literature Review. Vol. 9, *Children*. MDPI; 2022.
24. Farbu E, Rudolph T, Stefansdottir S. Guillain Barré syndrome - Incidence and clinical course in Southern Rogaland, Norway. *Clin Neurol Neurosurg*. 2016 Feb 1;141:33–7.
25. Zhang B, Duan L, Ma L, Cai Q, Wu H, Chang L, *et al*. Rapidly progressive Guillain–Barré syndrome following amitriptyline overdose and severe *Klebsiella pneumoniae* infection: A case report and literature review. *Front Med (Lausanne)*. 2022 Oct 4;9.
26. WDI - The World by Income and Region [Internet]. [cited 2023 Jan 12]. Available from: <https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html>
27. Siddiqui M, Majid S, Yusuf H, Mateen F. Electrophysiological Pattern and Predictors of Functional Outcome of Patients with Guillain Barre Syndrome

- at a Tertiary Care Hospital in Pakistan. *Journal of the College of Physicians and Surgeons Pakistan*. 2022 Mar 1;32(3):364–8.
28. Van Den Berg B, Storm EF, Garssen MJP, Blomkwist-Markens PH, Jacobs BC. Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation. *J Neurol Neurosurg Psychiatry*. 2018 Sep 1;89(9):949–54.
  29. Ilona Saputra R, Eko Purwata T, Ngurah Purna Putra Komang Arimbawa IG. Karakteristik studi konduksi saraf pasien sindrom Guillane-Barre di Rumah Sakit Umum Pusat Sanglah Denpasar. *Medicina (B Aires)*. 2019 Apr 15;50(1):76–80.
  30. Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Vol. 31, *Neurologic Clinics*. 2013. p. 491–510.
  31. Jung DY, Cho KT, Lee SC. Atypical guillain-barré syndrome misdiagnosed as lumbar spinal stenosis. *J Korean Neurosurg Soc*. 2013;53(4):245–8.
  32. Florian IA, Lupan I, Sur L, Samasca G, Timiş TL. To be, or not to be... Guillain-Barré Syndrome. *Autoimmun Rev*. 2021 Dec;20(12):102983.
  33. Créange A. Guillain-Barré syndrome: 100 years on. Vol. 172, *Revue Neurologique*. Elsevier Masson SAS; 2016. p. 770–4.
  34. Fujimura H. The Guillain-Barré syndrome. In: *Handbook of Clinical Neurology*. Elsevier B.V.; 2013. p. 383–402.
  35. Tandel H, Pandya N, Jani P, Vanza J. Guillain-barré syndrome (GBS): A Review. *Curr Med Res Opin*. 2016;3:366–71.
  36. Reyes-Vega MF, Soto-Cabezas MG, Soriano-Moreno AN, Valle-Campos A, Aquino-Peña F, Flores-Jaime N, *et al*. Clinical features of Guillain-Barré syndrome and factors associated with mortality during the 2019 outbreak in Peru. *J Neurol*. 2022 Jan 1;
  37. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome [Internet]. Vol. 7, [www.thelancet.com/neurology](http://www.thelancet.com/neurology). 2008. Available from: [www.thelancet.com/neurology](http://www.thelancet.com/neurology)
  38. Wahyu FF. Guillain-Barré syndrome: Penyakit Langka Beronset Akut yang Mengancam Nyawa. *Medula*. 2018 Apr;8(1):112–6.
  39. Yao J, Liu Y, Liu S, Lu Z. Regional Differences of Guillain-Barré Syndrome in China: From South to North. *Front Aging Neurosci*. 2022 Feb 1;14.
  40. Anderson TC, Leung JW, Harpaz R, Dooling KL. Risk of Guillain-Barré syndrome following herpes zoster, United States, 2010–2018. *Hum Vaccin Immunother*. 2021;17(12):5304–10.
  41. McKean N, Chircop C. Guillain-Barré syndrome after COVID-19 vaccination. *BMJ Case Rep*. 2021 Jul 30;14(7).
  42. Tabatabaee S, Rezania F, Alwedaie SMJ, Malekdar E, Badi Z, Tabatabaee SM, *et al*. Post COVID-19 vaccination Guillain-Barre syndrome: three cases. *Hum Vaccin Immunother*. 2022;18(5).

43. Li Y, Zhang X, Zhao C. Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. De Vleeschouwer S, editor. *Biomed Res Int*. 2021 Aug 19;2021:1–17.
44. El-Abassi RN, Soliman M, Levy MH, England JD. Treatment and Management of Autoimmune Neuropathies. In: Bertorini TE, editor. *Neuromuscular Disorders Treatment and Management*. 2nd ed. Missouri: Elsevier; 2022. p. 312–9.
45. Bao L, Chen X, Li Q, Zhang R, Shi H, Cui G. Surgery and Guillain-Barré syndrome: A single-center retrospective study focused on clinical and electrophysiological subtypes. *Neuropsychiatr Dis Treat*. 2020;16:969–74.
46. Gong Q, Liu S, Liu Y, Yao J, Fu X, Xiao Z, *et al*. Guillain-Barré syndrome triggered by surgery in a Chinese population: a multicenter retrospective study. *BMC Neurol*. 2021 Dec 1;21(1).
47. Van Den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain-Barré syndrome: Pathogenesis, diagnosis, treatment and prognosis. Vol. 10, *Nature Reviews Neurology*. Nature Publishing Group; 2014. p. 469–82.
48. Van Doorn PA. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). Vol. 42, *Presse Medicale*. Elsevier Masson SAS; 2013.
49. Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: From mechanisms to treatment. *Physiol Rev*. 2021 Jan 1;101(1):259–301.
50. Brealey D, Hirsch N. Diagnosis, assessment, and management of Guillain-Barré syndrome. In: *Oxford Textbook of Critical Care*. Oxford University Press; 2016. p. 1168–71.
51. Koreen R, DO JC. The Development of Guillain Barre Syndrome Subsequent to Administration of Ad26.COV2.S Vaccine. *Journal of Neurology Research Reviews & Reports*. 2021 Jun 30;1–3.
52. Zeng Y, Liu Y, Xie Y, Liang J, Xiao Z, Lu Z. Clinical Features and the Validation of the Brighton Criteria in Guillain-Barré Syndrome: Retrospective Analysis of 72 Hospitalized Patients in Three Years. *Eur Neurol*. 2019 Nov 1;81(5–6):231–8.
53. Bhagat SK, Sidhant S, Bhatta M, Ghimire A, Shah B. Clinical Profile, Functional Outcome, and Mortality of Guillain-Barre Syndrome: A Five-Year Tertiary Care Experience from Nepal. *Neurol Res Int*. 2019;2019.
54. Rath J, Zulehner G, Schober B, Grisold A, Krenn M, Cetin H, *et al*. Cerebrospinal fluid analysis in Guillain-Barré syndrome: value of albumin quotients. *J Neurol*. 2021 Sep 1;268(9):3294–300.
55. Tian J, Cao C, Li T, Zhang K, Li P, Liu Y, *et al*. Electrophysiological subtypes and prognostic factors of Guillain-Barre syndrome in northern China. *Front Neurol*. 2019;10(JUL).
56. Fokke C, Van Den Berg B, Drenthen J, Walgaard C, Van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. *Brain*. 2014;137(1):33–43.

57. Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Vol. 14, Human Vaccines and Immunotherapeutics. Taylor and Francis Inc.; 2018. p. 2568–79.
58. Irmak F. Management and treatment of pressure ulcers: Clinical experience. *SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital*. 2018;
59. Athanasopoulos KG, Papanastassiou ID, Drinis I, Groumas N, Gerochristou MA, Petropoulou K. A patient with Guillain-Barré syndrome and late recovery after 1 year. *J Musculoskelet Neuronal Interact*. 2019 Jun 1;19(2):226–8.
60. Darwin M, Mamondol MR, Sormin SA, Nurhayati Y, Tambunan H, Sylvia D, *et al*. Populasi dan Sampel. In: Tambunan TS, editor. *Metode Penelitian Pendekatan Kuantitatif*. Bandung: Media Sains Indonesia; 2021. p. 103–30.
61. Zhang G, Li Q, Zhang R, Wei X, Wang J, Qin X. Subtypes and prognosis of Guillain-Barré syndrome in southwest China. *PLoS One*. 2015 Jul 22;10(7).
62. Notoatmojo S. *Metodologi penelitian kesehatan*. 3rd ed. Jakarta: Rineka Cipta; 2018.
63. Yoshikawa H. Epidemiology of Guillain-Barré Syndrome. *Brain and nerve* . 2015 Nov;67(11):1305–11.
64. Armyta DN. THE EPIDEMIOLOGICAL OVERVIEW OF ACUTE FLACCID PARALYSIS CASES IN SURABAYA DURING 2014-2017. *Jurnal Berkala Epidemiologi*. 2019 Aug 30;7(2):163.
65. Kim AY, Lee H, Lee YM, Kang HY. Epidemiological features and economic burden of guillain-barré syndrome in south korea: A nationwide population-based study. *Journal of Clinical Neurology (Korea)*. 2021 Apr 1;17(2):257–64.
66. Sipilä JOT, Soilu-Hänninen M, Ruuskanen JO, Rautava P, Kytö V. Epidemiology of Guillain-Barré syndrome in Finland 2004–2014. *Journal of the Peripheral Nervous System*. 2017 Dec 1;22(4):440–5.
67. McCombe PA, Hardy TA, Nona RJ, Greer JM. Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis. Vol. 13, *Frontiers in Immunology*. Frontiers Media S.A.; 2022.
68. Kenan G, Regev T, Kushnir M, Cohen O, Gandelman-Marton R, Kimiagar I, *et al*. Reasons for delayed treatment initiation in Guillain-Barre syndrome. *J Neurol Sci*. 2022 Mar;434:120179.
69. Bose S, Loo LK, Rajabally YA. Causes and consequences of diagnostic delay in Guillain-Barré syndrome in a UK tertiary center. *Muscle Nerve*. 2022 May 15;65(5):547–52.
70. Dubey D, Kapotic M, Freeman M, Sawhney A, Rojas JC, Warnack W, *et al*. Factors contributing to delay in diagnosis of Guillain-Barré syndrome and impact on clinical outcome. *Muscle Nerve*. 2016 Mar 1;53(3):384–7.

71. Pathikonda C, Katyal N, Narula N, Govindarajan R. Disease and Patient Characteristics Contributing to Diagnostic Delays in Patients With Guillain-Barré Syndrome. *Front Neurol*. 2021 Jun 25;12.
72. Singh S, Gupta N, Gupta A, Chandel A, Waghela S, Saple P. Clinical profile and predictors for outcome in children presenting with Guillain-Barré syndrome. *J Family Med Prim Care*. 2020;9(10):5316.
73. Tunç A. Early predictors of functional disability in Guillain-Barré Syndrome. *Acta Neurol Belg*. 2019 Dec 1;119(4):555-9.
74. Ramahi AA, Katirji B, Devereaux M. Lower Motor Neuron Lesions. In: *Encyclopedia of the Neurological Sciences*. Elsevier; 2014. p. 918-22.
75. Zimmerman B, Hubbard JB. Deep Tendon Reflexes [Internet]. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2344316>
76. Rodriguez-Beato FY, De Jesus O. Physiology, Deep Tendon Reflexes [Internet]. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/6341874>
77. García A, Sedano MJ, Álvarez-Paradelo S, Berciano J. Reversible conduction failure on the deep tendon reflex response recording in early Guillain-Barré syndrome. *Clin Neurophysiol Pract*. 2018 Jan 1;3:159-63.
78. Chaudhary CW, Pasternak JJ. Diseases of the Autonomic and Peripheral Nervous Systems. In p. 321-31.
79. Wijdicks EFM, Klein CJ. Guillain-Barré Syndrome. Vol. 92, *Mayo Clinic Proceedings*. Elsevier Ltd; 2017. p. 467-79.
80. Papri N, Islam Z, Leonhard SE, Mohammad QD, Endtz HP, Jacobs BC. Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects. Vol. 17, *Nature Reviews Neurology*. Nature Research; 2021. p. 285-96.
81. Roodbol J, Korinthenberg R, Venema E, de Wit MCY, Lingsma HF, Catsman-Berrevoets CE, *et al*. Predicting respiratory failure and outcome in pediatric Guillain-Barré syndrome. *European Journal of Paediatric Neurology*. 2023 May 1;44:18-24.
82. Shang P, Feng J, Wu W, Zhang HL. Intensive Care and Treatment of Severe Guillain-Barré Syndrome. Vol. 12, *Frontiers in Pharmacology*. Frontiers Media S.A.; 2021.
83. Wang YZ, Lv H, Shi QG, Fan XT, Li L, Wong AHY, *et al*. Action mechanism of corticosteroids to aggravate Guillain-Barré syndrome. *Sci Rep*. 2015 Sep 10;5.